GenoSmart

Company Overview

Snapshot

Founded in March 2007 by Ofer Zohar, GenoSmart operated with 1–10 employees. The company raised $3.9M across one funding round and secured a grant from EU Horizon 2020 in September 2020. GenoSmart ceased operations in November 2024.

Business overview

GenoSmart developed proprietary bio-electronic molecular diagnostic devices for the rapid and accurate diagnosis of pathogens, including antibiotic-resistant bacteria and pandemic viruses. Its core technology, the Miniature Enthalpy-Meter (MEM), detects minute changes in the kinetic energy of molecules for rapid diagnostics. Additionally, the company created the Automated Nucleic Acid Extraction (ANAE) device for efficient purification of DNA or RNA. GenoSmart served the healthcare and life sciences sectors, focusing on medical devices and biotechnology for laboratories and healthcare providers.

Company Intelligence Q&A

What is GenoSmart's primary focus?

GenoSmart focuses on developing diagnostic solutions for the rapid and accurate diagnosis of pathogens using proprietary bio-electronic molecular diagnostic devices.

Who founded GenoSmart?

GenoSmart was founded by Ofer Zohar, who also served as the company's CTO.

What was the total capital raised by GenoSmart?

GenoSmart raised a total of $3.9M across one funding round.

What is the status of GenoSmart?

GenoSmart is non-active and ceased to operate in November 2024.

Did GenoSmart receive any grants?

In September 2020, GenoSmart secured a grant from EU Horizon 2020.